Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Wailoo

Showing results (11-20 of 64) with videos related to

Pageof 7
Sort By:
BMJ (Clinical Research Ed.)|March 6, 2004
Efficiency, equity, and NICE clinical guidelinesAllan Wailoo, Jennifer Roberts, John Brazier, et al.
Health and Quality of Life Outcomes|March 14, 2014
Modelling the relationship between the WOMAC Osteoarthritis Index and EQ-5DAllan Wailoo, Monica Hernandez Alava, Antonio Escobar Martinez
Clinical and Experimental Rheumatology|October 20, 2012
Payers' views on treating-to-target in rheumatoid arthritis: an English perspectiveIan C Scott, Allan Wailoo, David L Scott
Primary Health Care Research & Development|May 30, 2013
Variations in primary care prescribing: lessons to be learnt for GP commissionersRachel Houten, Allan Wailoo, Pall Jonsson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 7, 2025
Mapping EQ-5D-5L Utilities in Dementia: Integrating Self and Proxy ReportsHannah Hussain, Anju Keetharuth, Allan Wailoo, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 27, 2026
Switching from EQ-5D-3L to EQ-5D-5L in England: the impact in NICE technology appraisalsAline Navega Biz, Mónica Hernández Alava, Allan Wailoo
Rheumatology (Oxford, England)|August 24, 2011
The Sheffield rheumatoid arthritis health economic modelJonathan Tosh, Alan Brennan, Allan Wailoo, et al.
Health and Quality of Life Outcomes|November 19, 2022
Convergent validity of EQ-5D with core outcomes in dementia: a systematic reviewHannah Hussain, Anju Keetharuth, Donna Rowen, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 11, 2025
Enhancing HRQoL assessment for economic evaluation in dementia populationsHannah Hussain, Anju Keetharuth, Allan Wailoo, et al.
Pharmacoeconomics|August 11, 2018
The Impact of Moving from EQ-5D-3L to -5L in NICE Technology AppraisalsBecky Pennington, Monica Hernandez-Alava, Stephen Pudney, et al.
Pageof 7

Showing results (11-20 of 64) with videos related to

Sort By:
Pageof 7
BMJ (Clinical Research Ed.)|March 6, 2004
Efficiency, equity, and NICE clinical guidelinesAllan Wailoo, Jennifer Roberts, John Brazier, et al.
Health and Quality of Life Outcomes|March 14, 2014
Modelling the relationship between the WOMAC Osteoarthritis Index and EQ-5DAllan Wailoo, Monica Hernandez Alava, Antonio Escobar Martinez
Clinical and Experimental Rheumatology|October 20, 2012
Payers' views on treating-to-target in rheumatoid arthritis: an English perspectiveIan C Scott, Allan Wailoo, David L Scott
Primary Health Care Research & Development|May 30, 2013
Variations in primary care prescribing: lessons to be learnt for GP commissionersRachel Houten, Allan Wailoo, Pall Jonsson, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 7, 2025
Mapping EQ-5D-5L Utilities in Dementia: Integrating Self and Proxy ReportsHannah Hussain, Anju Keetharuth, Allan Wailoo, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 27, 2026
Switching from EQ-5D-3L to EQ-5D-5L in England: the impact in NICE technology appraisalsAline Navega Biz, Mónica Hernández Alava, Allan Wailoo
Rheumatology (Oxford, England)|August 24, 2011
The Sheffield rheumatoid arthritis health economic modelJonathan Tosh, Alan Brennan, Allan Wailoo, et al.
Health and Quality of Life Outcomes|November 19, 2022
Convergent validity of EQ-5D with core outcomes in dementia: a systematic reviewHannah Hussain, Anju Keetharuth, Donna Rowen, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 11, 2025
Enhancing HRQoL assessment for economic evaluation in dementia populationsHannah Hussain, Anju Keetharuth, Allan Wailoo, et al.
Pharmacoeconomics|August 11, 2018
The Impact of Moving from EQ-5D-3L to -5L in NICE Technology AppraisalsBecky Pennington, Monica Hernandez-Alava, Stephen Pudney, et al.
Pageof 7